中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2013年
8期
818-820
,共3页
亚临床型甲状腺功能减退症%甲状腺激素%蒙特利尔认知评估量表%认知功能
亞臨床型甲狀腺功能減退癥%甲狀腺激素%矇特利爾認知評估量錶%認知功能
아림상형갑상선공능감퇴증%갑상선격소%몽특리이인지평고량표%인지공능
Subclinical hypothyroidism%Thyroid hormone%Montreal cognitive assessment%Cognitive function
目的 探讨甲状腺激素替代治疗对老年原发性亚临床型甲状腺功能减退症(SCH)患者认知功能的影响.方法 选择临床确诊的老年SCH患者120例,采用左旋甲状腺素替代治疗6个月,对治疗前、后的甲状腺功能及认知功能损伤进行评估.结果 SCH患者激素替代治疗6个月后,促甲状腺激素(TSH)水平明显下降,与治疗前比较差异有统计学意义[(15.21±1.78) mU/L和(3.46±0.37)mU/L,t =6.417,P=0.0083]；甲状腺激素替代治疗6个月后,SCH患者在神经心理学实验中的画钟表试验、图像记忆、摆积木、复杂图形复制、复杂图形回忆及图形延迟回忆、词表延迟回忆、连线A、词表学习第1次、词表延迟回忆、词语再认、数字顺背、数字倒背、词语流畅性、数字符号实验均较治疗前有明显提高[(8.74±1.08)和(9.63±1.32),(6.14±1.03)和(8.47±1.38),(30.36±7.27)和(36.42±8.54),(13.71±1.05)和(14.87±1.38),(11.21±1.13)和(13.56±1.34),(11.36±1.27)和(13.06±1.47),(5.27±0.84)和(6.54±1.03),(63.13±12.09)和(54.63±10.07),(3.64±1.07)和(4.91±1.32),(5.27±0.84)和(6.54±1.03),(8.52±1.16)和(9.83±0.96),(8.01±0.83)和(8.94±1.08),(4.04±0.57)和(5.37±0.75),(11.21±1.03)和(13.43±1.23),(33.46±8.72)和(38.06±9.58)；t值分别为13.907、11.027、12.093、16.374、10.361、11.536、8.794、-10.617、9.601、8.794、17.814、7.913、12.415、13.992、10.128,P值分别为0.028、0.039、0.036、0.029、0.042、0.040、0.048、0.042、0.045、0.048、0.027、0.048、0.038、0.032、0.041].结论 甲状腺素替代治疗可以改善老年SCH患者的轻度认知功能损伤.
目的 探討甲狀腺激素替代治療對老年原髮性亞臨床型甲狀腺功能減退癥(SCH)患者認知功能的影響.方法 選擇臨床確診的老年SCH患者120例,採用左鏇甲狀腺素替代治療6箇月,對治療前、後的甲狀腺功能及認知功能損傷進行評估.結果 SCH患者激素替代治療6箇月後,促甲狀腺激素(TSH)水平明顯下降,與治療前比較差異有統計學意義[(15.21±1.78) mU/L和(3.46±0.37)mU/L,t =6.417,P=0.0083]；甲狀腺激素替代治療6箇月後,SCH患者在神經心理學實驗中的畫鐘錶試驗、圖像記憶、襬積木、複雜圖形複製、複雜圖形迴憶及圖形延遲迴憶、詞錶延遲迴憶、連線A、詞錶學習第1次、詞錶延遲迴憶、詞語再認、數字順揹、數字倒揹、詞語流暢性、數字符號實驗均較治療前有明顯提高[(8.74±1.08)和(9.63±1.32),(6.14±1.03)和(8.47±1.38),(30.36±7.27)和(36.42±8.54),(13.71±1.05)和(14.87±1.38),(11.21±1.13)和(13.56±1.34),(11.36±1.27)和(13.06±1.47),(5.27±0.84)和(6.54±1.03),(63.13±12.09)和(54.63±10.07),(3.64±1.07)和(4.91±1.32),(5.27±0.84)和(6.54±1.03),(8.52±1.16)和(9.83±0.96),(8.01±0.83)和(8.94±1.08),(4.04±0.57)和(5.37±0.75),(11.21±1.03)和(13.43±1.23),(33.46±8.72)和(38.06±9.58)；t值分彆為13.907、11.027、12.093、16.374、10.361、11.536、8.794、-10.617、9.601、8.794、17.814、7.913、12.415、13.992、10.128,P值分彆為0.028、0.039、0.036、0.029、0.042、0.040、0.048、0.042、0.045、0.048、0.027、0.048、0.038、0.032、0.041].結論 甲狀腺素替代治療可以改善老年SCH患者的輕度認知功能損傷.
목적 탐토갑상선격소체대치료대노년원발성아림상형갑상선공능감퇴증(SCH)환자인지공능적영향.방법 선택림상학진적노년SCH환자120례,채용좌선갑상선소체대치료6개월,대치료전、후적갑상선공능급인지공능손상진행평고.결과 SCH환자격소체대치료6개월후,촉갑상선격소(TSH)수평명현하강,여치료전비교차이유통계학의의[(15.21±1.78) mU/L화(3.46±0.37)mU/L,t =6.417,P=0.0083]；갑상선격소체대치료6개월후,SCH환자재신경심이학실험중적화종표시험、도상기억、파적목、복잡도형복제、복잡도형회억급도형연지회억、사표연지회억、련선A、사표학습제1차、사표연지회억、사어재인、수자순배、수자도배、사어류창성、수자부호실험균교치료전유명현제고[(8.74±1.08)화(9.63±1.32),(6.14±1.03)화(8.47±1.38),(30.36±7.27)화(36.42±8.54),(13.71±1.05)화(14.87±1.38),(11.21±1.13)화(13.56±1.34),(11.36±1.27)화(13.06±1.47),(5.27±0.84)화(6.54±1.03),(63.13±12.09)화(54.63±10.07),(3.64±1.07)화(4.91±1.32),(5.27±0.84)화(6.54±1.03),(8.52±1.16)화(9.83±0.96),(8.01±0.83)화(8.94±1.08),(4.04±0.57)화(5.37±0.75),(11.21±1.03)화(13.43±1.23),(33.46±8.72)화(38.06±9.58)；t치분별위13.907、11.027、12.093、16.374、10.361、11.536、8.794、-10.617、9.601、8.794、17.814、7.913、12.415、13.992、10.128,P치분별위0.028、0.039、0.036、0.029、0.042、0.040、0.048、0.042、0.045、0.048、0.027、0.048、0.038、0.032、0.041].결론 갑상선소체대치료가이개선노년SCH환자적경도인지공능손상.
Objective To investigate the effect of levothyrocine-thyroxine 4 (L-T4) replacement therapy on cognitive status in elderly patients with subclinical hypothyroidism (SCH).Methods One hundred and twenty elderly patients with SCH were selected and treated with thyroid hormone replacement therapy for 6 months.The thyroid functions and cognitive impairments were tested for all the subjects before and after the therapy.Results After 6 months of thyroid hormone replacement therapy,the level of thyrotropic hormone was significantly lower than that of before herapy((15.21 ± 1.78) mU/L vs.(3.46 ± 0.37) mU/L,t =6.417,P =0.0083));The neuropsyehological test performance in patients with hypothyroidism showed statistically significant improvements in clock drawing test,iconic memory,block design,complex graphics recall and delayed recall,trail making A,word list learningl,recall and recognize,forward and backward digital span,verbal fluency,and digital symbol from WAIS-RC ((8.74 ± 1.08) vs.(9.63 ± 1.32),(6.14 ± 1.03) vs.(8.47 ± 1.38),(30.36 ± 7.27) vs.(36.42 ±8.54),(13.71 ± 1.05) vs.(14.87 ± 1.38),(11.21 ± 1.13) vs.(13.56 ±1.34),(11.36 ± 1.27)vs.(13.06 ±1.47),(5.27 ±0.84) vs.(6.54 ±1.03),(63.13 ±12.09)vs.(54.63 ±10.07),(3.64 ± 1.07)vs.(4.91 ±1.32),(5.27 ±0.84) vs.(6.54±1.03),(8.52±1.16) vs.(9.83 ±0.96),(8.01 ± 0.83) vs.(8.94 ± 1.08),(4.04 ±0.57)vs.(5.37 ±0.75),(11.21 ± 1.03) vs.(13.43 ± 1.23),(33.46 ± 8.72) vs.(38.06 ± 9.58),t =13.907,11.027,12.093,16.374,10.361,11.536,8.794,-10.617,9.601,8.794,17.814,7.913,12.415,13.992,10.128 respectively,P =0.028,0.039,0.036,0.029,0.042,0.040,0.048,0.042,0.045,0.048,0.027,0.048,0.038,0.032,0.041 respectively).Conclusion The treatment of thyroid hormone for the edlerly patients with SCH has positive effects on theimprovement of mild cognitive impairment.
